Agrimony is a tannin-rich European herb from the Rosaceae family, used traditionally for mild diarrhea and inflammation of the oral and pharyngeal mucosa. Commission E approved it for mild nonspecific acute diarrhea and mild inflammation of the mucous membranes of the mouth and throat. The EMA granted traditional use status for mild diarrhea, symptomatic treatment of minor oral mucosal inflammation, and minor skin inflammation. No ESCOP monograph exists. The astringent action is attributed to catechin-type tannins (3-10%), particularly agrimoniin. Clinical evidence is essentially absent; approvals rely on pharmacological rationale and traditional use. The safety profile is favorable with no known drug interactions.

Angelica root (Angelicae radix) is a traditional European bitter aromatic herb approved by Commission E for loss of appetite and dyspeptic complaints (mild GI spasms, fullness, flatulence) and by EMA/HMPC for traditional use in mild spasmodic GI complaints and temporary loss of appetite. No ESCOP monograph exists. Its dual mechanism combines bitter-mediated digestive stimulation (via furanocoumarins and bitter principles) with spasmolytic activity from the essential oil components. Angelica root is notably a component of Iberogast (STW 5), the well-studied nine-herb combination product for functional dyspepsia and IBS. As a monotherapy, however, clinical trial evidence is essentially absent. An important safety consideration is the photosensitizing potential of its furanocoumarin content (angelicin, bergapten, imperatorin), and potential interactions with anticoagulant medications.

See full monograph below.

Boldo is a South American evergreen tree whose leaves have been used traditionally for dyspeptic complaints and mild GI spasms. Commission E approved boldo leaf for dyspepsia and mild spasmodic GI complaints, but neither ESCOP nor the EMA have issued monographs. The primary alkaloid boldine has choleretic and antioxidant properties. Clinical evidence is very limited, consisting mainly of pharmacological studies. The essential oil contains the toxic compound ascaridole and must not be used internally. Caution is warranted with anticoagulant medications due to boldine's antiplatelet effects.

See full monograph below.

Greater celandine was approved by the German Commission E for spastic complaints of the bile ducts and gastrointestinal tract, supported by its rich isoquinoline alkaloid profile (chelidonine, berberine, sanguinarine, coptisine) which exerts papaverine-like spasmolytic and choleretic effects. Limited clinical trial data -- including one placebo-controlled RCT (Ritter 1993) and the Cholagogum F Nattermann biliary dyskinesia trial -- showed modest benefit for functional dyspepsia and upper abdominal pain. However, the herb's risk-benefit profile has been fundamentally altered by reports of idiosyncratic hepatotoxicity (hepatocellular injury pattern, latency 1-6 months), leading to BfArM dose restrictions in Germany, refusal by the EMA/HMPC to adopt a monograph, and a broad reassessment of celandine's place in phytotherapy. Greater celandine also features as a component of STW 5 (Iberogast), the well-studied multi-herb formulation for functional dyspepsia.

Centaury is a European bitter herb from the Gentianaceae family, closely related to gentian, used traditionally for loss of appetite and dyspeptic complaints. Commission E approved it for dyspepsia and loss of appetite, and the EMA granted traditional use status for temporary appetite loss and mild dyspeptic complaints. No ESCOP monograph exists. The herb contains secoiridoid glycosides (swertiamarin, gentiopicroside) that activate bitter taste receptors to stimulate digestive secretions. Clinical evidence is essentially absent; all regulatory approvals are based on pharmacological plausibility and longstanding traditional use. The safety profile is favorable with no known drug interactions.

Dandelion is one of the most widely used traditional European medicinal plants, approved by Commission E for disturbances in bile flow, appetite loss, dyspepsia, and stimulation of diuresis. ESCOP recognizes it for restoration of hepatic and biliary function, dyspepsia, and loss of appetite. The EMA grants traditional use status for mild digestive disorders, temporary appetite loss, and increased urine output. Different plant parts have distinct emphasis: the root (Taraxaci radix) is primarily used for hepatobiliary and digestive complaints due to its sesquiterpene lactone and inulin content, while the herb/leaf (Taraxaci herba) is preferred for diuretic effects due to its high potassium content. Clinical trial evidence is very limited; the evidence base rests overwhelmingly on centuries of traditional use, pharmacological plausibility, and the well-characterized choleretic and diuretic properties of its constituents.

See full monograph below.

Fumitory is a Commission E-approved herb for colicky pain of the gallbladder, biliary system, and gastrointestinal tract. Its key alkaloid protopine exhibits a distinctive amphocholeretic effect, meaning it normalizes bile flow by increasing low bile secretion and decreasing excessive bile production. Fumitory is one of the traditional European "bitter" cholagogues with a history of use stretching back to Dioscorides and Galen. ESCOP and the EMA/HMPC also recognize its use for hepatobiliary digestive complaints, though the EMA limits it to traditional use status. Despite centuries of use and regulatory recognition, modern clinical trial evidence remains very limited, consisting of small, older studies. The herb is generally well tolerated at recommended doses.

See full monograph below.

See full monograph below.

See full monograph below.

See full monograph below.

See full monograph below.

See full monograph below.

See full monograph below.

Rhatany (Krameria lappacea, syn. K. triandra) is a South American shrub whose root has been used in European pharmacy since the 18th century primarily as an astringent for oral and pharyngeal inflammation. Commission E approved it for inflammation of the mouth and pharyngeal mucosa, and EMA grants traditional use status for minor inflammation of the oral mucosa and gums. The root is exceptionally rich in proanthocyanidin tannins (neolignans, including ratanhiaphenol) which exert astringent, anti-inflammatory, and antimicrobial effects by precipitating proteins on mucosal surfaces, forming a protective layer. Rhatany is commonly found in European herbal toothpastes and mouthwashes (notably Weleda Ratanhia products). Despite its long pharmaceutical history and continued presence in European pharmacies, no clinical trials have been conducted. ESCOP has not issued a monograph. The evidence base rests entirely on traditional use, pharmacological plausibility of tannin astringency, and regulatory approval.

Rosemary is a traditional European medicinal herb approved by Commission E for dyspeptic complaints (internal use) and as supportive therapy for rheumatic diseases (external use). The EMA grants traditional use status for mild digestive disorders and mild muscle/joint pain. ESCOP has not published a monograph for rosemary. The leaf contains rosmarinic acid, carnosic acid, carnosol, and a complex essential oil rich in 1,8-cineole, camphor, and borneol. Clinical trial evidence is very limited -- the evidence base rests primarily on pharmacological plausibility, long traditional use, and the well-characterized antioxidant and spasmolytic properties of its constituents. Rosemary occupies a complementary role alongside peppermint and other carminatives in the European phytotherapy approach to functional dyspepsia.

See full monograph below.

Slippery elm (Ulmus rubra) is a classic North American demulcent herb whose inner bark produces a thick mucilage when mixed with water. This mucilage forms a protective, soothing coating over irritated mucous membranes of the throat and gastrointestinal tract. It has deep roots in Native American traditional medicine and was adopted into the United States Pharmacopeia (USP) in the 19th century. The FDA classifies slippery elm bark as a safe and effective OTC oral demulcent, one of the few herbs with explicit FDA "safe and effective" recognition. Despite this regulatory recognition and centuries of traditional use, there are no published RCTs evaluating slippery elm as a monotherapy for any condition. The sole relevant clinical study used a multi-ingredient formula. The mucilage (approximately 7% of inner bark dry weight, composed of galactose, rhamnose, galacturonic acid, and 3-O-methylgalactose) provides the pharmacological rationale for the demulcent action. Slippery elm occupies a unique position: widely used, FDA-recognized, traditionally well-documented, but essentially unstudied in modern clinical trials. It has no European regulatory monographs (Commission E, ESCOP, EMA) as it is not part of the European phytotherapy tradition.

Tormentil (Potentilla erecta) rhizome is a highly astringent herb rich in tannins (15-22%, predominantly catechol-type including agrimoniin and pedunculagin) used traditionally in European phytotherapy for nonspecific acute diarrhea and inflammation of the oral and pharyngeal mucosa. It holds ESCOP and EMA/HMPC approval but lacks a Commission E monograph. Its primary mechanism is tannin-mediated astringency: tannins precipitate proteins on mucosal surfaces, forming a protective layer that reduces secretion, inflammation, and fluid loss. A small RCT in children with rotavirus diarrhea demonstrated reduced stool frequency and duration, but overall clinical evidence remains limited. Tormentil represents a classical European tannin drug (Gerbstoffdroge) with strong pharmacological plausibility but insufficient modern clinical trial data.

Triphala is the most widely used polyherbal formula in Ayurveda, consisting of equal parts dried fruits from three species: Amalaki (Emblica officinalis/Phyllanthus emblica), Haritaki (Terminalia chebula), and Bibhitaki (Terminalia bellirica). It functions as a gentle bowel regulator and antioxidant-rich GI tonic. Clinical trials demonstrate efficacy for chronic constipation (comparable to polyethylene glycol in one RCT), improvements in bowel habits, and benefits for dental/periodontal health. Key active compounds include gallic acid, ellagic acid, chebulinic acid, chebulagic acid, and high concentrations of vitamin C from Amalaki. Mechanisms include prokinetic effects, prebiotic activity supporting beneficial gut microbiota, antioxidant protection, and mild laxative action through anthraquinone content. No European regulatory monographs exist, but Triphala is one of the best-documented formulas in the Ayurvedic Pharmacopoeia of India.

See full monograph below.

Yarrow (Achillea millefolium) is one of the oldest and most broadly used medicinal plants in European folk medicine, with Commission E approval for loss of appetite and dyspeptic complaints, and EMA traditional use registration for appetite loss, mild GI spasms, and minor wound treatment. Despite centuries of use and pharmacologically plausible mechanisms (bitter-tonic appetite stimulation, spasmolytic flavonoids, anti-inflammatory proazulenes), yarrow has virtually no modern clinical trial evidence. It exemplifies the gap between long-established traditional use and the absence of controlled human studies. ESCOP has not issued a monograph. The evidence rating is low, resting almost entirely on traditional use documentation, pharmacological plausibility, and expert consensus.